focus -WSS

focus

author：knowledge 2025-10-01 22:39:28 - browse：93

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Designating disabled people as health disparity population is crucial

knowledge

WSS

A new nitrogen execution bill also undermines medical licensing

New menopause drug shows promise in relief for hot flashes

Risky weight loss products often used by teens globally, per study

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Readout LOUD podcast: live from JPM 2024

A solution to the after

hotspot

focus

entertainment

Psychedelics group wrestles with new pharma identity

New documents shed light on MD Anderson Cancer Institute feud

Trump demands the U.S. pay no more for drugs than other countries … again

GSK to buy asthma

Activists slam private health insurers over coverage restrictions

Alabama IVF ruling threatens families facing fatal genetic disease

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Harvard botanist who searched for psychedelics in the Amazon

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

knowledge

He's a Nobel laureate. Critics say he was misleading on Covid

Designating disabled people as health disparity population is crucial

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Alabama IVF ruling threatens families facing fatal genetic disease

Designating disabled people as health disparity population is crucial

6 phony surgeries that take placebo to the extreme

hotspot

knowledge

hotspot

explore